MELLARIL-S
LOE ApproachingNDAORALSUSPENSION
Approved
Oct 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MELLARIL-S is an oral suspension formulation of thioridazine, a typical antipsychotic small molecule approved in 1978. The drug's mechanism of action involves dopamine antagonism in the central nervous system. It is indicated for management of schizophrenia, behavioral disturbances, and other psychotic disorders in patients who require liquid dosage forms.
LOE Approaching
As LOE approaches, commercial teams are likely consolidating resources and preparing for market transition; headcount growth is unlikely.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MELLARIL-S offers minimal career growth opportunity; zero linked job openings and approaching LOE signal organizational disinvestment. Professionals assigned to this product should expect limited advancement and should consider transition planning to growth-stage assets.
Brand ManagerProduct Manager
Worked on MELLARIL-S at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.